Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457

1.

Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?

Obici L, Merlini G.

Mayo Clin Proc. 2018 Nov;93(11):1546-1548. doi: 10.1016/j.mayocp.2018.09.008. No abstract available.

PMID:
30392540
2.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
3.

Therapies for cardiac light chain amyloidosis: An update.

Aimo A, Buda G, Fontana M, Barison A, Vergaro G, Emdin M, Merlini G.

Int J Cardiol. 2018 Nov 15;271:152-160. doi: 10.1016/j.ijcard.2018.05.018.

PMID:
30223349
4.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

PMID:
30145929
5.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
6.

MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms.

Kourelis T, Murray DL, Dasari S, Kumar S, Barnidge D, Madden B, Arendt B, Milani P, Merlini G, Ramirez-Alvarado M, Kyle RA, Dispenzieri A.

Am J Hematol. 2018 Nov;93(11):E368-E370. doi: 10.1002/ajh.25244. Epub 2018 Sep 21. No abstract available.

PMID:
30105838
7.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

PMID:
30038381
8.

Outrageous prices of orphan drugs: a call for collaboration.

Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, Kääriäinen H, Garattini S, Hollak CE, Remuzzi G; Second Workshop on Orphan Drugs participants.

Lancet. 2018 Sep 1;392(10149):791-794. doi: 10.1016/S0140-6736(18)31069-9. Epub 2018 Jul 20. No abstract available.

PMID:
30037734
9.

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.

Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G.

Blood. 2018 Oct 4;132(14):1478-1485. doi: 10.1182/blood-2018-04-839480. Epub 2018 Jul 16. Review.

PMID:
30012636
10.

Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0194-x. [Epub ahead of print] No abstract available.

PMID:
29977017
11.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

PMID:
29972757
12.

Novel Therapies in Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. eCollection 2018 May. Review.

13.

Management of the elderly patient with AL amyloidosis.

Nuvolone M, Milani P, Palladini G, Merlini G.

Eur J Intern Med. 2018 May 22. pii: S0953-6205(18)30181-X. doi: 10.1016/j.ejim.2018.05.004. [Epub ahead of print]

PMID:
29801808
14.

Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M.

Circ Cardiovasc Imaging. 2018 May;11(5):e006588. doi: 10.1161/CIRCIMAGING.117.006588.

PMID:
29752392
15.

Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018022. doi: 10.4084/MJHID.2018.022. eCollection 2018. Review.

16.

The elusive pathogenesis of Schnitzler syndrome.

Palladini G, Merlini G.

Blood. 2018 Mar 1;131(9):944-946. doi: 10.1182/blood-2018-01-824862. No abstract available.

PMID:
29496698
17.

Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing.

Lavatelli F, Merlini G.

Proteomics. 2018 Apr;18(7):e1700353. doi: 10.1002/pmic.201700353. Epub 2018 Mar 8.

PMID:
29389069
18.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

PMID:
29386197
19.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

20.

New concepts in the treatment and diagnosis of amyloidosis.

Milani P, Palladini G, Merlini G.

Expert Rev Hematol. 2018 Feb;11(2):117-127. doi: 10.1080/17474086.2018.1424534. Epub 2018 Jan 10.

PMID:
29307226
21.

AL amyloidosis: from molecular mechanisms to targeted therapies.

Merlini G.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):1-12. doi: 10.1182/asheducation-2017.1.1. Review.

PMID:
29222231
22.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Oberti L, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7.

23.

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.

Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.

Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3.

24.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

PMID:
29101236
25.

Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

Nuvolone M, Merlini G.

Expert Opin Ther Targets. 2017 Dec;21(12):1095-1110. doi: 10.1080/14728222.2017.1398235. Review.

PMID:
29076382
26.

Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.

Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E.

Br J Haematol. 2017 Dec;179(5):748-755. doi: 10.1111/bjh.14966. Epub 2017 Oct 19.

PMID:
29048107
27.

The lung in amyloidosis.

Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170046. doi: 10.1183/16000617.0046-2017. Print 2017 Sep 30. Review.

28.

Attitudes about when and how to treat patients with AL amyloidosis: an international survey.

Milani P, Gertz MA, Merlini G, Dispenzieri A.

Amyloid. 2017 Dec;24(4):213-216. doi: 10.1080/13506129.2017.1370421. Epub 2017 Aug 31. Erratum in: Amyloid. 2017 Dec;24(4):256.

PMID:
28857614
29.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

30.

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

Circ Heart Fail. 2017 Jun;10(6). pii: e003815. doi: 10.1161/CIRCHEARTFAILURE.116.003815. Review.

PMID:
28611125
31.

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system.

Gonçalves NP, Moreira J, Martins D, Vieira P, Obici L, Merlini G, Saraiva M, Saraiva MJ.

J Neuroinflammation. 2017 Jun 6;14(1):115. doi: 10.1186/s12974-017-0891-9.

32.

Cardiac light-chain deposition disease relapsing in the transplanted heart.

Aimo A, Vergaro G, Pucci A, Bernazzali S, Maccherini M, Buda G, Passino C, Merlini G, Emdin M.

Amyloid. 2017 Jun;24(2):135-137. doi: 10.1080/13506129.2017.1334196. Epub 2017 May 31. No abstract available.

PMID:
28562083
33.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

34.

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G.

Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.

35.

How do we improve treatments for patients with amyloidosis using proteomics?

Lavatelli F, Merlini G.

Expert Rev Proteomics. 2017 Jul;14(7):561-563. doi: 10.1080/14789450.2017.1331737. Epub 2017 May 23. Review. No abstract available.

PMID:
28524784
36.

The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.

Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, Dasari S, Dispenzieri A.

Am J Hematol. 2017 Aug;92(8):772-779. doi: 10.1002/ajh.24772. Epub 2017 Jun 1.

37.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517. No abstract available.

PMID:
28434343
38.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis.

Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):60-61. doi: 10.1080/13506129.2017.1292901. No abstract available.

PMID:
28434342
39.

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G.

Amyloid. 2017 Mar;24(sup1):68-69. doi: 10.1080/13506129.2017.1293644. No abstract available.

PMID:
28434326
40.

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G.

Amyloid. 2017 Mar;24(sup1):66-67. doi: 10.1080/13506129.2017.1293643. No abstract available.

PMID:
28434323
41.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
42.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.

Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G.

Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916. No abstract available.

PMID:
28434293
43.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
44.

Regulated expression of amyloidogenic immunoglobulin light chains in mice.

Nuvolone M, Sorce S, Pelczar P, Rushing E, Lavatelli F, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A.

Amyloid. 2017 Mar;24(sup1):52-53. doi: 10.1080/13506129.2017.1289914. No abstract available.

PMID:
28434289
45.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Oct 26;55(11):1734-1743. doi: 10.1515/cclm-2016-1024.

PMID:
28343171
46.

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.

D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP.

Br J Haematol. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.

PMID:
28198999
47.

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.

Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L.

J Neurol Neurosurg Psychiatry. 2017 May;88(5):457-458. doi: 10.1136/jnnp-2016-315262. Epub 2017 Feb 10. No abstract available.

48.

Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage.

Diomede L, Romeo M, Rognoni P, Beeg M, Foray C, Ghibaudi E, Palladini G, Cherny RA, Verga L, Capello GL, Perfetti V, Fiordaliso F, Merlini G, Salmona M.

Antioxid Redox Signal. 2017 Sep 20;27(9):567-582. doi: 10.1089/ars.2016.6848. Epub 2017 Mar 3.

49.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S.

Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27.

50.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.

Supplemental Content

Loading ...
Support Center